{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:56:13Z","timestamp":1792454173929,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"publisher","award":["TTU-TB 02.709"],"award-info":[{"award-number":["TTU-TB 02.709"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031807","name":"M\u00e9decins Sans Fronti\u00e8res France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cmi.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:34:58Z","timestamp":1710336898000},"page":"1197.e1-1197.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe"],"prefix":"10.1016","volume":"30","author":[{"given":"Gunar","family":"G\u00fcnther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Kherabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.03.009_bib1","series-title":"Global tuberculosis report 2023","year":"2023"},{"key":"10.1016\/j.cmi.2024.03.009_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.009_bib3","first-page":"2331e43","article-title":"A\u00a024- week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.009_bib4","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.cmi.2024.03.009_bib6","doi-asserted-by":"crossref","first-page":"77e84","DOI":"10.1016\/j.cmi.2022.07.026","article-title":"Availability and costs of medicines for the treatment of tuberculosis in Europe","volume":"29","author":"Gu\u00a8nther","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.03.009_bib7","doi-asserted-by":"crossref","first-page":"341e4","DOI":"10.5588\/ijtld.23.0026","article-title":"Relative cost of multidrug-resistant TB medicines in Europe","volume":"27","author":"Gu\u00a8nther","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2024.03.009_bib8","doi-asserted-by":"crossref","first-page":"1685e93","DOI":"10.1093\/jac\/dkac070","article-title":"Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid","volume":"77","author":"Bateson","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.03.009_bib9","doi-asserted-by":"crossref","first-page":"1029e31","DOI":"10.1164\/rccm.201606-1097LE","article-title":"Limited bene\"t of the new shorter multidrug-resistant tuberculosis regimen in Europe","volume":"194","author":"Lange","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2024.03.009_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00388-2022","article-title":"Rifapentine access in Europe: growing concerns over key tuberculosis treatment component","volume":"59","author":"Guglielmetti","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2024.03.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00321-X","article-title":"Emerging bedaquiline-resistant tuberculosis","volume":"4","author":"Lange","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2024.03.009_bib12","article-title":"Mind the gap. Rolling out new drug resistant tuberculosis regimens with limited diagnostic tools","volume":"32","author":"Saluzzo","year":"2023","journal-title":"J\u00a0Clin Tuberc Other Mycobact Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:11:39Z","timestamp":1762366299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1198743X24001216"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.03.009","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}